Final Overall Survival Results of a Randomized Trial Comparing Bortezomib Plus Pegylated Liposomal Doxorubicin With Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma

BACKGROUND: Previous results from an interim analysis of an open-label, randomized, phase 3 study demonstrated that bortezomib combined with pegylated liposomal doxorubicin (PLD) was superior to bortezomib monotherapy in patients with relapsed/refractory multiple myeloma who had previously received...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cancer
Main Authors: Orlowski, Robert Z., Nagler, Arnon, Sonneveld, Pieter, Bladé, Joan, Hajek, Roman, Spencer, Andrew, Robak, Tadeusz, Dmoszynska, Anna, Horvath, Noemi, Spicka, Ivan, Sutherland, Heather J., Suvorov, Alexander N., Xiu, Liang, Cakana, Andrew, Parekh, Trilok, San-Miguel, Jesús F.
Format: Artigo
Jezik:Inglês
Izdano: 2016
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5701574/
https://ncbi.nlm.nih.gov/pubmed/27191689
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30026
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki